Table 1.
Baseline Characteristics
| Characteristic | NRF (n = 8) | SRI (n = 9) | ESRD (n = 9) |
|---|---|---|---|
| Age (years) | |||
| Median | 59.5 | 75.0 | 56.0 |
| Range | 42–68 | 63–87 | 39–80 |
| Female sex | 3 (38) | 3 (33) | 4 (44) |
| Race | |||
| White | 8 (100) | 6 (67) | 1 (11) |
| Black or African American | 0 | 2 (22) | 8 (89) |
| Asian | 0 | 1 (11) | 0 |
| Creatinine clearance (mL/min) | NAa | ||
| Mean | 105 | 26 | |
| Range | 84–146 | 15–33 | |
| ISS disease stage | |||
| I | 1 (13) | 2 (22) | 2 (22) |
| II | 3 (38) | 4 (44) | 1 (11) |
| III | 3 (38) | 3 (33) | 6 (67) |
| NR | 1 (13) | 0 | 0 |
| Disease status | |||
| Newly diagnosed | 1 (13) | 2 (22) | 0 |
| Refractory | 3 (38) | 2 (22) | 5 (56) |
| Relapsed | 3 (38) | 4 (44) | 4 (44) |
| Unknownb | 1 (13) | 1 (11) | 0 |
| Cytogenetics | |||
| del(17p) | |||
| Yes | 1 (13) | 2 (22) | 1 (11) |
| No | 7 (88) | 7 (78) | 8 (89) |
| t(14;16) | |||
| Yes | 1 (13) | 1 (11) | 0 |
| No | 5 (63) | 8 (89) | 8 (89) |
| NR | 2 (25) | 0 | 1 (11) |
| t(4; 14) | |||
| Yes | 1 (13) | 1 (11) | 0 |
| No | 6 (75) | 8 (89) | 9 (100) |
| NR | 1 (13) | 0 | 0 |
| Patients with ≥ 1 previous line of therapy | 7 (88) | 7 (78) | 9 (100) |
| Previous regimensc | |||
| Median | 2 | 2 | 2 |
| Range | 1–3 | 1–6 | 1–7 |
| Patients with previous therapies | |||
| Bortezomib | 5 (63) | 7 (78) | 9 (100) |
| Thalidomide | 3 (38) | 3 (33) | 5 (56) |
| Lenalidomide | 5 (63) | 2 (22) | 2 (22) |
Data presented as n (%), unless otherwise noted.
Abbreviations: ESRD = end-stage renal disease; ISS = International Staging System; NA = not available; NR = not reported; NRF = normal renal function; SRI = severe renal impairment.
a
Creatinine clearance was not required for patients in the ESRD group.
b
Refractory status to most recent line of therapy unknown.
c
Number of previous regimens applicable only to patients with relapsed or refractory disease.